Real World Evidence

Truven Launches AI Tool Cutting Data Feasibility Checks to Minutes

Truven Launches AI Tool Cutting Data Feasibility Checks to Minutes

Ann Arbor – September 29, 2026 -- Truven has launched MarketScan Snapshot, an AI-powered search capability that compresses what the company says can be days or weeks of cohort feasibility research into a process taking minutes.

Snapshot lets researchers query 300 million cumulative patient lives in plain language

The tool allows users to run patient-count requests against MarketScan Research Databases using everyday language, eliminating the need to specify medical codes or possess programming skills. MarketScan's underlying dataset includes more than 300 million cumulative lives, 95 million active lives, 99% claims completeness, and data access dating back to 1995 across commercial, Medicare and Medicaid populations.

FUCASO Hits 95.9% Response Rate in China Real-World Myeloma Study

Shanghai – September 27, 2026 -- IASO Biotechnology's CAR-T therapy FUCASO achieved a 95.9% objective response rate and 77.2% complete/stringent complete response rate in a real-world study of 281 heavily pretreated Chinese patients with relapsed or refractory plasma cell neoplasms, data presented at the 2026 International Myeloma Society Annual Meeting show.

Real-world cohort skews higher-risk than pivotal trial population

The multicenter study tracked patients treated since FUCASO's June 2023 launch across China. Median age was 61 years, with 18.7% aged 70 or older, and patients had received a median of four prior therapy lines, up to 12. Prior anti-CD38 exposure reached 84.0%, 27.4% were penta-exposed, and 46.9% had undergone autologous stem cell transplantation. High-risk cytogenetic abnormalities affected 82.4% of patients, 50.5% were ISS stage III, 7.8% had plasma cell leukemia, and 47.0% presented extramedullary disease.